-transparent.png){kind=logo}
MDL 73005EF has been recently described as a potent, highly selective 5-HT1A ligand. Although proposed to act predominantly as an antagonist (M. Hibert, A.K. Mir, G. Maghioros, P. Moser, D.N. Middlemiss, M.D. Trickleband and J.R. Fozard, 1988, The Pharmacological properties of MDL 73005EF: a potent and selective ligant at 5-HT1A receptors, Br. J. Pharmacol. 93, 2P), we have demonstrated that MDL 73005EF also acts as a highly efficacious partial agonist at the 5HT1A receptor, based on its ability to inhibit forskolin-stimulated adenylate cyclase in rat hippocampal membranes. Compared with two structurally related 5-HT1A partial agonists, the rank order of potency of MDL 73005EF in the FSC assay was comparable to affinity calculated by radioligand binding.
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
November 1992,
European journal of pharmacology,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
August 1991,
European journal of pharmacology,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
April 1991,
European journal of pharmacology,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
December 1990,
European journal of pharmacology,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
January 1993,
Biochemical pharmacology,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
May 1992,
Cell biology international reports,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
January 1990,
Neuroreport,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
March 1983,
Pharmacological reviews,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
April 2002,
European journal of pharmacology,
L J Cornfield, and
D L Nelson, and
E W Taylor, and
A R Martin
February 1999,
Neuropharmacology,
